These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 23251644)

  • 1. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.
    Budczies J; Klauschen F; Sinn BV; Győrffy B; Schmitt WD; Darb-Esfahani S; Denkert C
    PLoS One; 2012; 7(12):e51862. PubMed ID: 23251644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator.
    Ogłuszka M; Orzechowska M; Jędroszka D; Witas P; Bednarek AK
    Comput Methods Programs Biomed; 2019 Aug; 177():133-139. PubMed ID: 31319941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
    Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
    Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.
    Hupperets PS; Volovics L; Schouten LJ; Jager JJ; Schouten HC; Hillen HF; Blijham GH
    Am J Clin Oncol; 1997 Dec; 20(6):546-51. PubMed ID: 9391537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
    Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.
    Morrison DH; Rahardja D; King E; Peng Y; Sarode VR
    Br J Cancer; 2012 Jul; 107(2):382-7. PubMed ID: 22713661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of carcinoma breast: grade and estrogen progesterone receptor expression.
    Kamil M; Khalid I; Hashim H; Biswas M; Kaur G; Islam R
    J Coll Physicians Surg Pak; 2010 Apr; 20(4):250-2. PubMed ID: 20392401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
    Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
    Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular aspects of estrogen receptor variants in breast cancer.
    Fuqua SA; Wolf DM
    Breast Cancer Res Treat; 1995 Sep; 35(3):233-41. PubMed ID: 7579493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.